| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 9, 2025
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that BrainSense™ Adaptive Deep Brain Stimulation (aDBS) – the world's first closed-loop DBS system for...
-
Sep 19, 2025
The Implantable Tibial Neuromodulation (ITNM) device will expand treatment options for the 16 million people living with urinary urges and involuntary leaks GALWAY, Ireland, Sept. 19, 2025 /PRNewswire
-
Feb 24, 2025
New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever GALWAY, Ireland, Feb. 24, 2025...
-
Sep 25, 2024
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced today at the North American Spine Society (NASS) 39th Annual Meeting in Chicago the commercial launch of several...
-
Apr 26, 2024
Closed-loop sensing capability instantly and automatically adjusts therapy while treating chronic pain DUBLIN, April 26, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in...
-
Jan 8, 2024
Rechargeable neurostimulator joins the Medtronic Percept™ family – the first and only deep brain stimulation system with sensing, directionality, and advanced programming. DUBLIN, Jan. 8, 2024...
-
Aug 25, 2023
Inceptiv automatically and instantly adjusts therapy based on signals from the spinal cord DUBLIN, Aug. 25, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology,...
-
Oct 26, 2022
New Medtronic Neurovascular Co-Lab™ Platform drives collaboration and connections among start-ups, physicians, and institutions; aims to improve stroke treatment and access for patients...
-
Jul 14, 2022
Powered by a database of over 10,000 surgical cases, Medtronic continues to evolve the UNiD™ platform to help surgeons plan procedures, personalize care for their patients and predict...
-
May 13, 2022
Acquisition adds innovative bioabsorbable steroid-eluting sinus implants to ENT portfolio DUBLIN and MENLO PARK, Calif., May 13, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in...
-
Mar 24, 2022
TITAN 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy DUBLIN, March 24, 2022 /PRNewswire/ -- Medtronic plc (NYSE:...
-
Mar 23, 2022
Medtronic and Harris Poll survey finds 4 in 5 report chronic back or leg pain is worse or unimproved since the COVID-19 pandemic began DUBLIN, March 23, 2022 /PRNewswire/ -- A new survey...
-
Feb 28, 2022Single-use device treats Eustachian tube dysfunction during office procedures
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the launch of the NuVent™ Eustachian tube dilation balloon, which has been cleared by the U.S. Food and Drug...
-
Feb 22, 2022- New InterStim X™ system provides 10 to 15 years of battery life without the need to recharge
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for InterStim X™ ― the next generation...
-
Jan 24, 2022Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration approval of its Intellis™ rechargeable neurostimulator and...
-
Jan 14, 2022
DTM™ SCS endurance therapy enables long-lasting recharge-free performance on Vanta™ and 5-minute recharge on Intellis™ neurostimulators DUBLIN, Jan. 14, 2022 /PRNewswire/ -- Medtronic plc...
-
Jan 12, 2022
Sessions will include DTM™ SCS endurance therapy 3-month outcomes for patients with chronic back and leg pain DUBLIN, Jan. 12, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in...
-
Dec 13, 2021Study shows 57.1% of patients discontinued or reduced oral opioid prescription refills post-procedure and exhibited a decrease in payer costs¹
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the results of a study published in Osteoporosis International that demonstrate a decrease, and in some cases...
-
Sep 30, 2021Industry Leading Portfolio of Integrated Solutions Sets a New Standard for Minimally Invasive Spine Procedures, Beginning with MIS+ TLIF
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery ecosystem, making it the only company to combine...
-
Sep 28, 2021- Portfolio Features First Catheter Specifically Designed to Allow Neurointerventionalists Radial Artery Access, Delivers Advantages to Patients Treated for Stroke, Brain Aneurysms, Other Neurovascular Conditions
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE Mark approval for its radial artery access portfolio, which includes the Rist™ 079 Radial...
-
Sep 22, 2021Medtronic Will Move to Request Litigation Proceedings Resume
Medtronic (NYSE:MDT), the global leader in medical technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed an additional...
-
Sep 22, 2021
As First Patient Is Enrolled in the Clinical Trial of Braive™ Growth Modulation System, Study Reaffirms Medtronic's Commitment to Pediatric Spine Innovation DUBLIN, Sept. 22, 2021 /PRNewswire/...
-
Sep 13, 2021Medtronic Receives Affirmation of Three Additional Sacral Neuromodulation Patents
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has won three additional important victories in a dispute over its intellectual property (IP) for its sacral...
-
Aug 6, 2021Acquisition to Add Innovative Bioabsorbable Drug Release Platform to Chronic Rhinosinusitis Portfolio
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with Intersect ENT (NASDAQ: XENT), a global ear, nose, and throat...
-
Jun 10, 2021Vanta™ Implantable Neurostimulator Offers Up to 11 Year Battery Life and Personalized Pain Relief
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for Vanta™, a high performance recharge-free...
